Jubilant Pharmova has received approval from the US Food and Drug Administration (USFDA) for commercial batch manufacturing of the first product on Line 3, a new isolator-based fill-and-finish line at its contract manufacturing facility in Spokane, Washington. According to reports from CNBC TV18, the company announced the development on Sunday, August 23, stating the approval was received on August 22 at 1:16 am IST. The newly approved Line 3 represents a significant expansion of the company's manufacturing capabilities at its Spokane facility, marking a capacity and capability expansion in sterile injectables and ophthalmics for the group. By bringing Line 3 into commercial service, Jubilant Pharmova can offer additional, modern fill-and-finish capacity to pharmaceutical and biopharmaceutical customers seeking reliable U.S.-based manufacturing partners. This development strengthens the company's contract manufacturing franchise in North America and potentially enhances its competitiveness and growth prospects in highly regulated markets.
The facility is operated by Jubilant HollisterStier LLC (JHS), a subsidiary of Jubilant Pharma Holding Inc., which in turn is a subsidiary of Jubilant Pharma Limited, Singapore, a wholly owned subsidiary of Jubilant Pharmova. As reported by CNBC TV18, Jubilant HollisterStier is an integrated contract manufacturer of sterile injectables, including liquid and lyophilised products, as well as ophthalmic products such as ointments, liquids and creams. The company provides contract manufacturing services to pharmaceutical and biopharmaceutical companies, covering manufacturing processes from process qualification through commercial release. The isolator-based technology employed in the Line 3 facility is expected to streamline and enhance the safety of production processes, ensuring high-quality products for the pharmaceutical and biopharmaceutical industries. This development supports the company's broader integrated CDMO strategy, reinforcing its role as a key supplier to global drugmakers and signaling operational progress that may underpin future contract wins and revenue growth in its sterile injectables business.
Jubilant Pharmova reported a 45.1% year-on-year decline in consolidated PAT attributable to owners to ₹56.4 crore in Q1FY27, despite a 17.3% rise in revenue to ₹2,229.4 crore. According to CNBC TV18, EBITDA fell 14.4% to ₹248 crore, while the margin narrowed to 11.1% from 15.2%. The company said revenue growth was broad-based, led by CDMO Sterile Injectables, but profitability was affected by the absence of high-margin SPECT radiopharmaceutical products, negligible third-party revenues and higher operating expenses, including Montreal remediation costs.
CDMO Sterile Injectables revenue rose 34% to ₹496 crore, while revenue from the Spokane facility increased 43% to ₹494 crore and EBITDA rose 49% to ₹117 crore. As reported by CNBC TV18, Drug Discovery Services revenue grew 8% to ₹174 crore, while Generics revenue increased 4% to ₹173 crore. The company operates contract development and manufacturing facilities for sterile injectables in Spokane, US, and Montreal, Canada, offering manufacturing solutions including sterile fill-and-finish injectables and ophthalmic products.
Shares of the company ended 0.68% higher at ₹877 on Friday ahead of the USFDA approval announcement. According to CNBC TV18, the stock has declined more than 17% so far in 2026 and nearly 19% over the last 12 months. The company announced that commercial batch production of SPECT radiopharmaceuticals has started after successful media-fills, with batches expected to be released in Q2FY27. All SPECT radiopharmaceutical products are expected to be available by the second half of FY27, marking a significant milestone for the company's radiopharmaceutical capabilities. This development strengthens the company's contract manufacturing franchise in North America and potentially enhances its competitiveness and growth prospects in highly regulated markets.
